Previous close | 38.25 |
Open | 38.25 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 38.25 - 38.25 |
52-week range | 11.83 - 41.75 |
Volume | |
Avg. volume | 185 |
Market cap | 2.232B |
Beta (5Y monthly) | 0.92 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.24 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 22.46 |
Company announcement – No. 24 / 2023 Total number of shares and voting rights in Zealand Pharma at May 31, 2023 Copenhagen, Denmark, May 31, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar mo
Company announcement – No. 23 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 25, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities
Company announcement – No. 22 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, May 23, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 23,491 divided into 23,491 new shares with a nominal value of DKK 1 each. The increas
Zealand Pharma A/S (ZLDPF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Company announcement - No. 20 / 2023 Zealand Pharma Announces Financial Results for the First Quarter of 2023 Positive topline data from obesity portfolioOn track for two regulatory submissions targeting rare diseasesStrengthened balance sheet with DKK 1.5 billion in April resulting in a runway to mid-2026 Copenhagen, Denmark, May 11, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areasFull data will be presented at the 2023 American Diabetes Association’s 83rd Scientific SessionsNovel dual glucagon/GLP-1 receptor agonist BI 456906 is part of the collaboration between Boehr
Press Release– No. 3 / 2023 Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results Copenhagen, Denmark, May 4, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 11, 2023, at 2:00 pm CET (8:00 am ET) following the announcement of results for the first quarter of 2023. Presenting during the call
Company announcement – No. 18 / 2023 Total number of shares and voting rights in Zealand Pharma at April 28, 2023 Copenhagen, Denmark, April 28, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calenda
Company announcement – No. 15 / 2023 Zealand Pharma launches long-term incentive program for Zealand’s Board of Directors, Corporate Management and employees for 2023 Copenhagen, Denmark, April 19, 2023 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of a long-term incentive program (the “LTIP”) for Zealand's Board of Directo
Press release – No. 2 / 2023 Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference Copenhagen, Denmark, April 12, 2023 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will present an overview of the company at the 22nd Annual Needham Virtual Healthcare Conference. Date: Wednesday, April 19, 2023Presentation: 8:00 a.m. ET /
Company announcement – No. 14 / 2023 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN
Company announcement – No. 13 / 2023 Zealand Pharma A/S publishes a listing prospectus regarding admission to trading and official listing of 6,578,948 new shares on Nasdaq Copenhagen NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SO
Company announcement – No. 12 / 2023 Total number of shares and voting rights in Zealand Pharma at March 31, 2023 Copenhagen, Denmark, March 31, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calenda
Company announcement – No. 11 / 2023 Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE
Company announcement – No. 10 / 2023 Zealand Pharma announces directed issue and private placement of approximately 6.5 million new shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION E
Company announcement – No. 9 / 2023 Zealand Pharma's Annual General Meeting 2023 Copenhagen, March 29, 2023 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting of 2023 as a partly electronic general meeting. At the meeting, all proposals presented to the General Meeting were adopted. The General Meeting acknowledged the management's report on Zealand's activities in the past financial year and Zealand's audited Annual Report for 2022 was
Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396In development as a non-incretin peptide therapy for the potential management of overweight and obesity Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on t
Company announcement – No. 6 / 2023 Zealand Pharma Provides Update on Silicon Valley Bank Closure Update to company announcement No.5 following joint statement by U.S. Treasury, Federal Reserve, and FDIC: Depositors at SVB will have access to all of their money starting Monday, March 13Zealand now expects to recover all of its deposits held at SVB, Monday March 13 Copenhagen, Denmark March 13, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the disc
Company announcement – No. 5 / 2023 Zealand Pharma Provides Statement on Silicon Valley Bank Closure Copenhagen, Denmark March 12, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today issued the following statement: On March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (SVB) and appointed the Federal Deposit Insurance Corpor
Correction: Company Announcement – No. 2 / 2023 Zealand convenes its Annual General Meeting 2023 Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Wednesday, March 29 2023 at 3:00 pm (CEST) The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (h
Company announcement – No. 1 / 2023 Correction: Zealand Pharma Announces Full Year Results for 2022 Successful organizational transformation and progress across the R&D pipelineTwo regulatory submissions anticipated in programs targeting rare diseasesStrong momentum within obesity portfolio with key data expected during 2023 Copenhagen, Denmark March 2, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative pepti
Company Announcement – No. 2 / 2023 Zealand convenes its Annual General Meeting 2023 Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Wednesday, March 29 2023 at 3:00 pm (CEST) The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meetin
Company announcement – No. 1 / 2023 Zealand Pharma Announces Full Year Results for 2022 Successful organizational transformation and progress across the R&D pipelineTwo regulatory submissions anticipated in programs targeting rare diseasesStrong momentum within obesity portfolio with key data expected during 2023 Copenhagen, Denmark March 2, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based med
Press release – No. 1 / 2023 Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022 Copenhagen, Denmark February 24, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on March 2, 2023 at 2:00 pm CET (8:00 am ET) following the announcement of results for the full year of 2022. Pr
Company announcement – No. 58 / 2022 Total number of shares and voting rights in Zealand Pharma at December 30, 2022 Copenhagen, Denmark and Boston, MA, U.S. December 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Compa